September 28, 2020 10:29 AM EDT

Aligos Therapeutics, developing several different hep B and NASH treatments, files for $100M IPO raise

Another biotech filed to go public late Friday as the 2020 IPO party rages on.

Aligos Therapeutics, focusing on chronic hepatitis B and NASH …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ali­gos Ther­a­peu­tics, de­vel­op­ing sev­er­al dif­fer­ent hep B and NASH treat­ments, files for $100M IPO raise